Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
about
Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloofA comprehensive review on metabolic syndromeRole of insulin in the type 2 diabetes therapy: past, present and futureManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryMetformin for people with impaired glucose tolerance or impaired fasting blood glucoseAlpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucoseAlpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucoseAlpha-glucosidase inhibitors for type 2 diabetes mellitusMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesStabilization of high-risk plaquesCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Continued efforts to translate diabetes cardiovascular outcome trials into clinical practicePancreatic regulation of glucose homeostasisThe metabolic vascular syndrome - guide to an individualized treatmentPolypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 DiabetesAcarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomesGlycemic Variability: How Do We Measure It and Why Is It Important?Therapeutic Use of Metformin in Prediabetes and Diabetes PreventionCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsImpact of postprandial glycaemia on health and prevention of diseaseBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingShould antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?Glycemic control and cardiovascular disease: what's a doctor to do?β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Update on the treatment of type 2 diabetes mellitusUpdate on pre-diabetes: Focus on diagnostic criteria and cardiovascular riskDiagnosis and management of the metabolic syndrome in obesityThe cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker ratsA physarum-inspired prize-collecting steiner tree approach to identify subnetworks for drug repositioningImprovement of Glucose Metabolism in Patients with Impaired Glucose Tolerance or Diabetes by Long-Term Administration of a Palatinose-Based Liquid Formula as a Part of BreakfastSummation of blood glucose and TAG to characterise the 'metabolic load index'.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Therapy insight: heart disease and the insulin-resistant patient.The glucose triad and its role in comprehensive glycaemic control: current status, future management.Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus.The prevention of type 2 diabetes.Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies.
P2860
Q21246039-D802360E-B4C8-4792-BC2F-DF2B94C5A2EDQ21284500-EC67868A-B2CA-4AE1-95F3-6C4638507612Q22241148-5F080D24-0F10-4FB2-A238-63FCDB29EEF3Q22241288-A1F9C9F4-1A8B-4671-A125-612C5C6B2B85Q22241786-F370B2D1-6F70-4907-9FE6-EBCEDE9A00C1Q24235225-83136203-B1A7-4451-B11E-A520279DDC95Q24244041-E00F8236-E363-44EB-ABFF-524E96D6F9B3Q24246432-C69AD4BE-12D7-4874-9D75-3067DFBEC768Q24246908-261C195C-07A3-47FB-BDCF-78E9F60C33C7Q24642503-06234EC0-E7C0-4F6E-A6F8-4D175BBC4BD5Q26738584-0A897E10-9DB1-462B-9A1B-67C6CFB908EFQ26740253-F4B6D31D-26B9-4805-BD28-D4D1C36BF3DFQ26741860-829F4B18-8473-43E8-8534-4E69046D901DQ26766485-445ACFE8-7581-46A3-946A-96E103F0970BQ26767142-83232C19-0F38-42F9-8284-56874C2F2E17Q26767283-C57E71B5-A96D-4427-809A-4FA5B14868DDQ26778095-D8288316-35E9-4FCE-95DA-E3A7A8BB0193Q26795377-38A96369-B8ED-4582-9827-08C03289F2DFQ26822066-2FED40E6-FF3A-48E7-9D4A-49B5A053722BQ26824616-02D098CE-E8AD-48CE-9331-665E6046A728Q26862823-9D1C2A13-33A6-4A39-A9FA-11968D49D9BCQ26992979-7A9B3BDB-5299-4A69-9841-61F123A984B5Q27022813-854D224B-4A72-4CCF-BD50-225C8D1860DCQ27024469-88C6EA55-D555-4E0E-B60D-B8D824481CFEQ27692665-BB0FAF53-3352-4934-B46E-CDD986E493FEQ28073342-431B184F-45EA-4AC1-9621-1B4E1D51657DQ28073749-1ED24C1A-78AC-44EA-88AC-3E0ABB679D20Q28192856-EE82A4CB-CD6C-4B8D-9918-456354656843Q28579415-C06E5F48-1C97-439A-826D-7975B3B70FC0Q28818655-FA430274-4ED7-4512-A7DE-D303C4FD7A21Q28972240-B0A0CC9A-F3E1-4A28-A52F-B1FD5AA9019BQ30244149-7DBE2959-1F41-418B-B6A8-C7C8B58CD4C8Q30249371-FDE457A1-BCFE-4A64-8B22-82EC735BE512Q30351748-749A997E-C266-4C42-B5EF-3A76A4F254FAQ30393989-14A4BB24-D1C0-4F06-ABA1-DFBDCDA23627Q30438126-6253FE4E-7210-4DD2-98E5-BB7C3770930CQ30438605-4EF567AD-2D62-4F74-90ED-29C451117EFBQ30484253-C2A80EC3-1EA4-4FC0-9D6B-B92E602D83F5Q30887632-3AC0B9CB-7DF5-4036-BE8E-41137CEBDC8EQ33350900-D2DDD0CA-E102-4CE8-844A-AD6504298594
P2860
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Acarbose treatment and the ris ...... lerance: the STOP-NIDDM trial.
@en
Acarbose treatment and the ris ...... lerance: the STOP-NIDDM trial.
@nl
type
label
Acarbose treatment and the ris ...... lerance: the STOP-NIDDM trial.
@en
Acarbose treatment and the ris ...... lerance: the STOP-NIDDM trial.
@nl
prefLabel
Acarbose treatment and the ris ...... lerance: the STOP-NIDDM trial.
@en
Acarbose treatment and the ris ...... lerance: the STOP-NIDDM trial.
@nl
P2093
P921
P356
P1476
Acarbose treatment and the ris ...... lerance: the STOP-NIDDM trial.
@en
P2093
Avraham Karasik
Jean-Louis Chiasson
Ramon Gomis
Robert G Josse
STOP-NIDDM Trial Research Group
P304
P356
10.1001/JAMA.290.4.486
P407
P577
2003-07-01T00:00:00Z